Forte Biosciences’ $40 Million Public Offering

Wilson Sonsini Goodrich & Rosati advised Forte Biosciences on the deal.

Forte Biosciences, a clinical-stage biopharmaceutical company, announced the pricing of an underwritten public offering of 1,403,509 shares of its common stock at a price to the public of $28.50 per share. In addition, Forte has granted the underwriters a 30-day option to purchase up to an additional 210,256 shares of common stock at the public offering price, less underwriting discounts and commissions.

Forte intends to use the net proceeds of the offering for working capital and general corporate purposes, which include, but are not limited to, the funding of clinical development of, and pursuing regulatory approval for, its product candidates, and general and administrative expenses. The aggregate gross proceeds from the offering are expected to be approximately $40 million, before deducting the underwriting discounts and commissions and offering expenses payable by Forte and excluding any exercise of the underwriters’ option to purchase additional shares.

The Wilson Sonsini team advising Forte Biosciences was led by Dan Koeppen (Picture) and also included Tom Hornish, Benjamin Capps, Brandon Shaw, Michael Hostetler and David Harburger.

Involved fees earner: Benjamin Capps – Wilson Sonsini Goodrich & Rosati; David Harburger – Wilson Sonsini Goodrich & Rosati; Tom Hornish – Wilson Sonsini Goodrich & Rosati; Michael Hostetler – Wilson Sonsini Goodrich & Rosati; Dan Koeppen – Wilson Sonsini Goodrich & Rosati;

Law Firms: Wilson Sonsini Goodrich & Rosati;

Clients: Forte Biosciences, Inc;

Print Friendly, PDF & Email

Author: Ambrogio Visconti